1. Scrip
  2. >>Therapy Areas
  3. >>Sensory

Panic Not, Say Analysts As Apellis’s Syfovre Launch Is Beset By Retinal Vasculitis Events

Stock Down By 38%

 
• By Ayisha Sharma

The US firm’s Syfovre for geographic atrophy due to age-related macular degeneration was linked with a handful of cases of occlusive retinal vasculitis, according to a letter published by a top retinal society, but most analysts believe there is a reasonable explanation.  

3d graphic of cross-section of eye in doctor's hand
42% Of Eyes With Geographic Atrophy Are Classed As Legally Blind • Source: Shutterstock

Apellis Pharmaceuticals, Inc.’s Syfovre is taking the heat following the publication of a letter recommending doctors exercise caution after a few instances of a previously unseen safety event emerged in the real world setting, although several analysts remained unfazed and projected a continued successful launch.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Sensory

In Brief: US FDA Rejects Regeneron’s Bid to Extend Eylea HD Dosing

 
• By Sushmita Panda

Regeneron is disappointed by the knock-back for longer dosing intervals for its high-dose version of Eylea, but its supplemental application for a more commercially important shorter four-week regimen has received a priority review.

Outlook Holds Out Hope For Wet AMD Approval Despite Phase III Topline Miss

 
• By Alaric DeArment

The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.

GSK’s Linerixibat GLISTENs In PBC Itching

 
• By Elizabeth Cairns

But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.

Clearside Clears Way For Phase III After Positive CLS-AX Results In Wet AMD

 
• By Alaric DeArment

The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.

More from Therapy Areas

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.